echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA approves new compound therapy Entadfi for common diseases in middle-aged and elderly men

    FDA approves new compound therapy Entadfi for common diseases in middle-aged and elderly men

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 13, 2021, Veru announced that the US FDA has approved Entadfi for the treatment of urinary tract symptoms caused by benign prostatic hyperplasia (BPH)


    BPH is a common disease in middle-aged and elderly men and one of the main causes of lower urinary tract symptoms.


    ▲The curative effect result of finasteride and tadalafil in combination (picture source: Veru official website)

    Veru's Entadfi is a unique compound formula that meets the FDA's bioavailability and bioequivalence standards compared with taking finasteride and tadalafil at the same time


    Reference materials:

    [1] Veru Announces FDA Approval of Entadfi, a New Treatment for Benign Prostatic Hyperplasia.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.